Sage Journals: Discover world-class research

Abstract

Introduction: Age-related macular degeneration (AMD) is a degenerative retinal disorder leading to central vision loss. This study investigates the association between AMD and sleep quality and sleep duration. Methods: Our team examined a variety of published literature, such as case series, clinical trials, and economic studies. These studies were retrieved from the online databases of peer-reviewed literature, CINHAL, EMBASE, and MEDLINE, as well as literature that was published, but not peer reviewed. We used the statistical analysis software STATA 15.0 to assess for any overall relationships between AMD and sleep quality, sleep duration, or both. Results: Nine articles, with a total of 4,502 subjects, were used to conduct the meta-analysis. There were significantly higher Pittsburgh Sleep Quality Index (PSQI) scores (greater than 5) among AMD patients: effect size (ES) = 0.52, 95%; confidence interval (CI): (0.38, 0.65). These scores indicate that individuals with AMD often have higher PSQI scores, suggesting poorer sleep quality. Furthermore, the meta-analysis showed significantly higher rates of insomnia among AMD patients: ES = 0.02, 95%; CI: (0.01, 0.03). The effect of AMD on sleep time was nonsignificant: ES = 0.04, 95%; CI: (–0.17, 0.25). The odds ratio for sleep time over 8 hr was also not significant among patients with AMD: ES = 0.99, 95%; CI: (0.64, 1.52). Discussion: The findings highlight a significant association between AMD and poor sleep quality, evidenced by higher PSQI scores and increased rates of insomnia among AMD patients. The disruptions in sleep are likely due to the psychological stress associated with vision loss related to AMD, as well as potential disruptions in melatonin synthesis and circadian rhythms. Implications for Practitioners: These results emphasize the need for targeted interventions, such as cognitive-behavioral therapy and melatonin supplementation, to improve sleep quality in this population. Additional studies are needed to elucidate the underlying mechanisms of sleep disturbances in AMD and to assess the efficacy of these treatments.

Keywords

Age-related macular degeneration (AMD) is a chronic degenerative retinal disorder that leads to gradual central vision loss. Approximately 0.37% of older adults in the global population experience permanent visual impairment, including blindness, due to late-stage AMD (Jong, 2006; Wong et al., 2014). Concerningly, the prevalence of late-stage AMD is predicted to surge by 86% between 2014 and 2040, reaching a staggering 9.92 million affected individuals worldwide, compared to 4.59 million in 2014 (Wong et al., 2014).

AMD is linked to sleep disruptions, depression, anxiety, and worse quality of life, all indicating significant psychosocial impairment (Cimarolli et al., 2015; Hassell et al., 2006; Khurana et al., 2016; Maynard et al., 2017; Mitchell & Bradley, 2006). Sleep disturbances may manifest as trouble falling asleep or staying asleep and the experience of daytime drowsiness (Roth & Roehrs, 2003). Sleep disturbances are common, with estimated rates ranging from 8% to 22% (Cappuccio et al., 2010; Ohayon, 2002). Roughly 50% of adults over 65 years of age experience insomnia symptoms, reflecting the increased sleep difficulties that are common with advanced age (Cappuccio et al., 2010). Sleep disturbances can affect both health and overall quality of life, resulting in diminished physical well-being and cognitive abilities (Chattu et al., 2018; Lee et al., 2009; Worley, 2018). Both excess and insufficient sleep are linked to adverse health outcomes such as hypertension and cardiovascular disease, which are also associated with increased AMD risk (Cappuccio et al., 2011; Chakravarthy et al., 2010; Hyman et al., 2000). Evidentially, sleep disturbances impose

☑ Earn CEs Online

by answering questions on this article.

For more information, visit:

https://www.aerelearning.org/

a considerable burden on society and are associated with increasing healthcare costs (Hillman et al., 2006). Given the broad effect of AMD on both physical and mental health, we believe that recognizing the relationship between this pathology and sleep length or quality of sleep is of the utmost importance. The results of this paper may aid a range of health care practitioners, including physicians and mental health and rehabilitation counsellors, in optimizing the holistic care of patients who have AMD and experience concurrent sleep disturbances.

Several mechanisms might explain the relationship between AMD and sleep dysfunction. Visual impairment from AMD can disrupt the sleep cycle (Adeoti & Akang, 2010). The retina is instrumental in sleep regulation via photoentrainment. Intrinsically photosensitive retinal ganglion cells (ipRGCs) depend on light perception to regulate the suprachiasmatic nucleus, our body's internal clock, which is responsible for governing the sleep–wake cycle (Maynard et al., 2017). Sleep disturbances in individuals who have AMD could also stem from disrupted melatonin production. Melatonin is mainly produced by the pineal gland and is key to the regulation of the sleep–wake cycle (Hardeland et al., 2006). Nocturnal serum melatonin levels decrease with advancing age and are associated with age-related diseases like AMD (Bubenik & Konturek, 2011; Chattoraj et al., 2009; Iguchi et al., 1982). Reduction in melatonin levels in AMD patients is concerning, since melatonin protects against oxidative stress, a significant risk factor implicated in the development and progression of AMD (AREDS, 2000; Chakravarthy et al., 2010). The link between AMD and sleep dysfunction involves a complex and bidirectional interplay, where each condition can potentially influence and exacerbate the other. The relationship between AMD and sleep is not fully understood, since existing research suggests poor sleep quality is linked to AMD, while other studies indicate no significant difference in sleep quality between patients with and without AMD. Despite the significance of this relationship, no previous meta-analysis has investigated the effects of AMD on sleep quality. Therefore, we aim to explore the relationship between AMD and sleep quality to enhance the management of AMD and improve patients’ quality of life.

Methods

Search Strategy

This systematic review and meta-analysis adhered to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines (see Appendix A). We conducted comprehensive searches of the CINAHL, EMBASE, and MEDLINE databases up to August 1, 2023, as outlined in Appendix B. In addition, we manually searched for relevant poster presentations or abstracts from conferences organized by the American Academy of Ophthalmology, Canadian Ophthalmological Society, and the Association for Research in Vision and Ophthalmology. Grey literature was also reviewed, including sources from ProQuest Dissertations and Theses Global and ClinicalTrials.gov. Detailed information on the gray literature searches can be found in Appendix B.

Inclusion Criteria

Studies were included if they investigated the effects of AMD in sleep of adults 18 years and older. Although AMD is primarily a disease that is associated with aging, it may occur in individuals as young as 30 years of age. An inclusion criterion of patients above 18 years of age ensures all studies documenting these cases are included in our analysis. Despite the poorer prognosis associated with wet AMD compared to dry AMD, no distinction was made due to the limited studies available. The effects of AMD on sleep were assessed by looking at measures including, but not limited to, sleep time, sleep quality, insomnia, and the Pittsburgh Sleep Quality Index (PSQI) scores. Insomnia was diagnosed either by clinical diagnosis by a physician, self-reported measures, or standardized questionnaires. Included in the review were case series, clinical trials, cohort studies, comparative studies, economic studies, observational studies, and randomized controlled trials.

Exclusion Criteria

Case reports, case series, letters to editors, commentaries, review articles, systematic reviews, and meta-analyses were excluded. If sufficient study details and data were provided, then conference abstracts were included. Studies that were not published in English were omitted to prevent potential inconsistencies that could arise during translation. This study did not impose any restrictions on geographical location or publication year.

Study Selection

We uploaded the collected literature into Covidence, a systematic review tool, where an automated duplicate check was conducted, followed by a manual verification by one of the reviewers. The screening process was conducted in three stages. Initially, title and abstract screening (levels 1 and 2) included all studies addressing the effects of AMD on sleep. The full-text screening (level 3) focused on studies that examined at least 20 adult eyes and reported outcomes related to sleep duration, quality, insomnia, and PSQI scores. Two reviewers independently assessed the studies at each stage, resolving any discrepancies through discussion. If an agreement could not be reached, a third reviewer was consulted. The Cohen's kappa (κ) coefficient was calculated for each screening stage to ensure reliability. Figure 1, presented as the PRISMA flowchart, depicts the number of studies at each screening stage.

Figure 1.

Prisma Flowchart. Note: The flowchart is for the systematic review outlining the number of database searches, the number of abstracts screened, and full-text articles reviewed for study eligibility, and reasons for exclusion. From: Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group. (2009). Preferred reporting items for systematic reviews and meta analyses: the PRISMA statement. PLoS Med, 6(6), Article e1000097. https://doi.org/10.1371/journal.pmed.1000097.

Risk of Bias Assessment

A modified Downs and Black Checklist (Downs & Black, 1998) was utilized for assessing the risk of bias. To ensure methodological integrity, each article included in this systematic review and meta-analysis underwent a rigorous quality evaluation.

Data Collection Process

Table 1 displays the study characteristics of the 10 studies extracted. This included author, study design, year of publication, study location, sample size, sleep duration, prevalence of insomnia, and PSQI scores. Studies were categorized based on their risk of bias assessment scores: those scoring 15 or below were classified as low quality, scores from 16 to 19 were considered medium quality, and scores over 20 were deemed high quality. Given the limited evidence available, no low-quality studies were excluded from the analysis. For a detailed explanation of the risk of bias assessment, please see Appendix C.

Table 1.

Summary of Included Studies’ Characteristics.

Author	Year	Study Design	Study Location	N	Mean Age	SD
Anastasopoulos et al.	2018	Cross-sectional	Greece	904	71.1	-
Khurana et al.	2016	Cross-sectional	USA	503	80	-
Lee et al.	2020	Cross-sectional	Korea	53	-	-
Maynard et al.	2017	Case control	Australia	53	78.8	8.8
Murphy et al.	2015	Cross-sectional	Canada	43	81.51	-
Nau	2017	Case control	USA	441	-	-
Perez-Canales et al.	2016	Case control	Spain	57	79.25	6.46
Purbrick et al.	2014	Cross-sectional	England	77	78	-
Sharma et al.	2021	Case control	India	277	68.3	9.086
Tsai et al.	2020	Case control	Taiwan	2,094	67.9	-

Statistical Analysis

We used STATA 15.0 software (STATA Corporation, College Station, TX) to perform the meta-analysis. The proportion metric was employed to evaluate the effect size or treatment outcome. To assess the degree of heterogeneity among studies, we calculated the I² value, which signifies the variance attributable to heterogeneity rather than random chance. The Chi-squared test was used to determine whether the observed variances among studies were likely random. Significant heterogeneity was indicated by a low p-value in conjunction with a high Chi-squared statistic relative to its degrees of freedom. Depending on the level of heterogeneity, we chose either fixed-effect or random-effect models. Forest plots and funnel plots were utilized to visually display the results and to identify any potential publication bias.

Results

Search Results

We identified 626 articles from online databases and grey literature. Among these, 170 duplicates were removed. Following a review of titles and abstracts, we excluded 434 papers due to irrelevance. This left 22 articles for an in-depth full-text review, of which 10 were chosen for data analysis. One study was not incorporated into the meta-analysis due to noncomparable data. Therefore, the meta-analysis included nine studies with a total of 4,501 subjects. Articles were excluded if they were deemed irrelevant or did not pass the screening criteria. The Cohen's kappa (κ) values were 0.79 for title and abstract screening and 0.38 for full-text review.

Study Characteristics

Table 1 provides a breakdown of the demographic characteristics of the 10 studies that qualified for our review, including the one study that was disqualified from the meta-analysis. Five of these studies were case-control studies, while the remaining five were cross-sectional studies. The research was conducted in various global locations, such as Australia, Canada, India, Korea, Spain, and the United States. Study populations varied in size, from 43 to 2,094. Although not every study disclosed a mean age for participants, the majority focused on older populations, with average ages spanning from 67.9 to 81.51 years.

Impact of AMD on Sleep Quality Using PSQI Scores

PSQI serves as a self-assessment tool for evaluating sleep quality and disruptions (Buysse et al., 1989). Comprising 19 questions, this instrument examines seven sleep facets: perceived sleep quality, time taken to fall asleep, total sleep time, regular sleep efficiency, sleep interruptions, reliance on sleep medications, and daytime challenges. These individual component scores are aggregated to produce a global score, which can vary between 0 and 21. A higher score signifies poorer sleep quality. A PSQI score greater than 5 is generally considered to indicate poor sleep quality and suggests that the individual has significant sleep disturbances or difficulty sleeping.

Figure 2 demonstrates heterogeneity in the studies analyzing the effect of AMD on PSQI scores: >5 (I² = 69.8%, p = .445). Studies reported a significantly higher prevalence of PSQI scores among patients with AMD: >5 (ES 0.52, 95%; CI: [0.38, 0.65]).

Figure 2.

Forest Plot of Pooled Effect Size (ES) for Pittsburgh Sleep Quality Index (PSQI). Note: Score comparing age-related macular degeneration (AMD) patients versus controls. Note: Positive ES indicates a higher (worse) PSQI score in AMD.

Impact of AMD on Insomnia

Figure 3 reveals heterogeneity among the studies evaluating the impact of AMD on rates of insomnia (I² = 79.7%, p = .026). Studies reported a significant impact on insomnia among patients with AMD: ES 0.02, 95%; CI: (0.01, 0.03).

Figure 3.

Forest Plot of Pooled Effect Size (ES) for Insomnia Comparing AMD Patients Versus Controls. Note: Positive ES indicates greater insomnia burden in AMD.

Impact of AMD on Sleep Time

Figure 4 shows heterogeneity among studies investigating the effects of AMD on sleep time (I² = 92.0%, p = .000). Studies reported a nonsignificant impact on sleep time among patients with AMD: ES 0.04, 95%; CI: −0.17, 0.25).

Figure 4.

Forest Plot of Pooled Effect Size (ES) for Sleep Duration Comparing AMD Patients Versus Controls. Note: Positive ES indicates longer sleep duration in AMD.

Impact of AMD on Odds Ratio for Sleep Time Over 8 Hours

Figure 5 indicates there was no significant heterogeneity between studies examining the impact on odds ratio for sleep time over 8 hr (I² = 0.0%, p = .445). Studies reported a nonsignificant odds ratio for sleep time over 8 hr among patients with AMD: ES 0.99, 95%; CI: (0.64, 1.52).

Figure 5.

Forest Plot of Pooled Odds Ratio (OR) for Long Sleep Duration (>8 hr) Comparing AMD Patients Versus Controls. Note: OR > 1 indicates higher odds of sleeping >8 hr in AMD.

Assessment of Study Quality and Publication Bias

The majority of the studies evaluated using the Modified Downs and Black Checklist (Downs & Black, 1998) achieved scores of 15 or higher, indicating they were “good” quality (n = 9). Only one study scored between 11 and 14 (n = 1), categorizing it as of poor quality. Articles of lower quality were not excluded from our analysis due to limited evidence. Detailed information on the risk of bias assessment is provided in Appendix C.

Publication Bias

Figures 6 through 9 illustrate funnel plots for PSQI scores above 5 (Figure 6), insomnia prevalence among AMD patients (Figure 7), the average sleep duration (Figure 8), and the odds ratio for sleep exceeding 8 hr (Figure 9). The plots for these figures show studies spread from the top left to the bottom right. A visual inspection of the funnel plots did not reveal any noticeable asymmetry. The few studies at the bottom suggest that smaller studies with nonsignificant findings might be unpublished.

Figure 6.

Funnel Plot for Studies Evaluating Pittsburgh Sleep Quality Index (PSQI) Score in AMD.

Figure 7.

Funnel Plot for Studies Evaluating Insomnia in AMD.

Figure 8.

Funnel Plot for Studies Evaluating Sleep Duration in AMD.

Figure 9.

Funnel Plot for Studies Evaluating Odds of Long Sleep Duration (>8 hr) in AMD.

Discussion

Background

Our study entailed a meta-analysis exploring the relationship between AMD and sleep quality. Our meta-analysis revealed a significant increase in the prevalence of poor sleep quality among AMD patients (Maynard et al., 2017; Murphy et al., 2015; Purbrick et al., 2014). Similar observations of poor sleep quality have been observed in visually impaired patients with eye conditions like diabetic retinopathy and glaucoma (Chew et al., 2020; Chin et al., 2020). The impact of AMD on mental health, including depression, anxiety, stress, and reduced quality of life, could further deteriorate sleep quality (Cimarolli et al., 2015; Hassell et al., 2006; Mitchell & Bradley, 2006). Chronic illness diagnosis has been found to heighten patient stress and arousal, leading to less restorative sleep (Parish, 2009).

Analysis

Our meta-analysis revealed an increased prevalence of insomnia among AMD patients (Nau, 2017; Tsai et al., 2020). It is important to note that the definition of insomnia does not rely on a specific number of hours of sleep, since each person has unique sleep requirements. Instead, insomnia is characterized by various sleep changes, such as a prolonged amount of time needed to fall asleep, frequent nighttime awakenings, or extended periods of wakefulness during sleeping periods (Roth, 2007). There was no significant correlation found between AMD and sleep duration, including sleep time exceeding 8 hr (Khurana et al., 2016; Maynard et al., 2017; Murphy et al., 2015; Purbrick et al., 2014; Tsai et al., 2020). This finding is consistent with a previous study that also did not establish any significant link between sleep duration and AMD (Hanscom & Kreiger, 1980). Additionally, a different study also reported no correlation between sleep duration and AMD, but, interestingly, it observed longer sleep times (greater than 8 hr) among individuals with geographic atrophy or significant visual impairments (Khurana et al., 2016).

Impact of AMD on Sleep Quality

Age-related macular degeneration (AMD) can significantly affect a person's mental health, leading to poor sleep quality. Depression and anxiety, often associated with AMD, are well-known contributors to sleep disturbances (Senra et al., 2019). Additionally, psychosocial stressors such as difficulty performing daily activities, loss of autonomy, and impaired social interactions further degrade sleep quality in AMD patients (Lane et al., 2018; Taylor et al., 2016). The persistent fear of worsening vision, potential blindness (Enoch et al., 2024), and anxiety about treatments like anti–vascular endothelial growth factor (VEGF) injections exacerbate these stressors (Senra et al., 2022), resulting in disrupted sleep. Furthermore, visual hallucinations, which can be distressing, may also contribute to poor sleep quality (Carpenter et al., 2019; Pang, 2015). Addressing the mental health challenges faced by AMD patients is crucial in managing their sleep quality and overall well-being.

Physiology of Sleep in AMD

The increased prevalence of poor sleep quality and insomnia in AMD patients provides strong evidence of underlying sleep dysfunction in this population. This finding has also been observed in several studies involving visually impaired individuals (Lockley et al., 1997; Lockley et al., 2007; Mistlberger & Skene, 2005; Revell & Skene, 2010; Sack et al., 1992). One potential cause of poor sleep quality and insomnia in AMD patients is the disruption of the circadian rhythm. In humans, the circadian rhythm governs various physiological processes in a near 24-hr cycle and is regulated by the suprachiasmatic nucleus (SCN) (Saper et al., 2005). This central clock in the brain synchronizes with the solar day through light information received from intrinsically photosensitive retinal ganglion cells (ipRGCs), which, in turn, influences the secretion of melatonin, a hormone critical for sleep and circadian rhythm regulation (Berson et al., 2002; Czeisler, 1995; Hillman et al., 2006; Martínez-Águila et al., 2021). Degeneration of the macula may disrupt the photic signals transmitted to the SCN, leading to irregular melatonin synthesis and subsequent sleep disturbances. Consequently, this disruption in the circadian rhythm could be a significant contributing factor to the observed poor sleep quality and insomnia seen in AMD patients.

Melatonin secretion is disrupted in individuals with AMD. Research has demonstrated that nocturnal melatonin levels in the serum decrease with age (Bubenik & Konturek, 2011; Iguchi et al., 1982; Jung et al., 2010). This decline has been linked with age-related diseases, such as AMD (Bubenik & Konturek, 2011; Jung et al., 2010). Arylalkylamine N-acetyltransferase (AANAT), a crucial enzyme in melatonin synthesis and the regulation of circadian rhythm, is found to be decreased with AMD (Julio & Clifford, 1986; Rosen et al., 2009). Moreover, a study has reported approximately 40% lower levels of urinary 6-sulfatoxymelatonin, a reliable biomarker of melatonin synthesis, in AMD patients (Rosen et al., 2009). Lower levels of melatonin could contribute to an increased prevalence of insomnia and poor sleep quality in AMD patients.

It is important to consider that sleep disturbances can affect the development and progression of AMD. Poor sleep quality can cause oxidative stress, a key contributor to AMD, which can lead to retinal damage and chronic inflammation (AREDS, 2000; Chakravarthy et al., 2010; Everson et al., 2005). Melatonin, known for its antioxidant properties, plays a protective role by mitigating oxidative stress in the retina (Morvaridzadeh et al., 2020). Furthermore, fragmented sleep has been linked to increased atherosclerotic risk, potentially compromising blood flow and oxygenation to the eye and exacerbating AMD progression through inflammatory-mediated pathways (Vallat et al., 2020). Hence, addressing sleep disturbances and promoting healthy sleep patterns may hold potential benefits in managing AMD and its associated complications. This bidirectional relationship between sleep disturbances and AMD highlights the complex interplay and mutual influence of these factors on pathophysiology. It may also be the reason that sleep quality appears to be affected in patients with AMD, but not the sleep quantity. Reason may suggest that only patients with reduced sleep quality, despite adequate duration, experience the negative consequences of oxidative stress, leading to the development of AMD. This observation may give further insight into the directionality of the relationship between AMD and sleep. However, more research is needed to elucidate the specific reason that there appears to be a detriment of sleep quality but not duration in patients with AMD.

Limitations

The limitations of this study include a lack of adjustments for common risk factors for AMD, such as age, smoking status, and genetic polymorphisms. Additionally, there were no adjustments for common risk factors associated with insomnia or poor sleep, including age, gender, occupation, and general health status. These unaccounted factors may influence the associations found between AMD and sleep quality, potentially limiting the reliability and generalizability of the results. Future research should consider these variables to provide a more comprehensive understanding of the relationship between AMD and sleep disturbances.

Another limitation is that we were unable to differentiate between mild and severe AMD (e.g., geographic atrophy). This lack of differentiation restricted our ability to assess potential differences in sleep duration, as seen in another study showing longer sleep duration among those with severe visual impairment and geographic atrophy in AMD (Pérez-Canales et al., 2016). As previously stated, we were also unable to selectively identify the relationship between wet and dry AMD, with regard to their impact on sleep duration, quality, or both. Our inability to distinguish the findings between the disease variants serves as a potential limitation, given that there may be differences between how strongly either form is correlated with an impact on sleep (Hackett et al., 2018).

Another limitation is that the relationship between sleep and AMD is intricate and bidirectional, making it challenging to determine causal factors definitively. Psychosocial factors further complicate the understanding of this relationship, making it difficult to discern whether AMD affects sleep or vice versa. The relationship between sleep and AMD is complex, and AMD can cause sleep disturbances. It is crucial to be vigilant about sleep issues caused by AMD and seek medical attention to address and manage them effectively to preserve vision and prevent worsening outcomes.

Conclusion

Although AMD is primarily a degenerative retinal disorder, its implications extend beyond the eye. The condition can profoundly affect mental health and quality of life, contributing to depression, anxiety, and social isolation. Exploration of cognitive behavioral therapy and melatonin supplementation to improve sleep quality in this population may be warranted. Understanding AMD's broader effects emphasizes the need for comprehensive patient care that includes psychological support and interventions to improve overall quality of life, not just ocular health.

Supplemental Material

sj-docx-1-jvb-10.1177_0145482X261425228 - Supplemental material for The Effects of Age-Related Macular Degeneration on Sleep Quality and Sleep Duration: A Meta-Analysis

Supplemental material, sj-docx-1-jvb-10.1177_0145482X261425228 for The Effects of Age-Related Macular Degeneration on Sleep Quality and Sleep Duration: A Meta-Analysis by Edward Tran, Vivian Phu, Mohamed Aly, Nirmit Shah, Cindy Hutnik and Monali S. Malvankar-Mehta in Journal of Visual Impairment & Blindness

Supplemental Material

sj-docx-2-jvb-10.1177_0145482X261425228 - Supplemental material for The Effects of Age-Related Macular Degeneration on Sleep Quality and Sleep Duration: A Meta-Analysis

Supplemental material, sj-docx-2-jvb-10.1177_0145482X261425228 for The Effects of Age-Related Macular Degeneration on Sleep Quality and Sleep Duration: A Meta-Analysis by Edward Tran, Vivian Phu, Mohamed Aly, Nirmit Shah, Cindy Hutnik and Monali S. Malvankar-Mehta in Journal of Visual Impairment & Blindness

Supplemental Material

sj-docx-3-jvb-10.1177_0145482X261425228 - Supplemental material for The Effects of Age-Related Macular Degeneration on Sleep Quality and Sleep Duration: A Meta-Analysis

Supplemental material, sj-docx-3-jvb-10.1177_0145482X261425228 for The Effects of Age-Related Macular Degeneration on Sleep Quality and Sleep Duration: A Meta-Analysis by Edward Tran, Vivian Phu, Mohamed Aly, Nirmit Shah, Cindy Hutnik and Monali S. Malvankar-Mehta in Journal of Visual Impairment & Blindness

Footnotes

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

Glaucoma Research Society of Canada

ORCID iDs

Edward Tran

Nirmit Shah

Supplemental Materials

Supplemental materials for this article are available online.

References

Adeoti

Akang

E. E.

(2010). Disorders of the sleep–wake cycle in blindness. West African Journal of Medicine, 29(3), 163–168.

Age-Related Eye Disease Study Group (AREDS). (2000). Risk factors associated with age-related macular degeneration: AREDS study report number 3. Ophthalmology, 107(12), 2224–2232. https://doi.org/10.1016/S0161-6420(00)00409-7

Anastasopoulos

Haidich

A. B.

Coleman

A. L.

Wilson

M. R.

Harris

Koskosas

Pappas

Keskini

Kalouda

Karkamanis

Topouzis

(2018). Risk factors for age-related macular degeneration in a Greek population: The thessaloniki eye study. Ophthalmic Epidemiology, 25(5–6), 457–469. https://doi.org/10.1080/09286586.2018.1512634

Berson

D. M.

Dunn

F. A.

Takao

(2002). Phototransduction by retinal ganglion cells that set the circadian clock. Science, 295(5557), 1070–1073. https://doi.org/10.1126/science.1067262

Bubenik

G. A.

Konturek

S. J.

(2011). Melatonin and aging: Prospects for human treatment. Journal of Physiology and Pharmacology, 62(1), 13–19.

Buysse

D. J.

Reynolds

C. F.

Monk

T. H.

Berman

S. R.

Kupfer

D. J.

(1989). The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Research, 28(2), 193–213. https://doi.org/10.1016/0165-1781(89)90047-4

Cappuccio

F. P.

Cooper

D’Elia

Strazzullo

Miller

M. A.

(2011). Sleep duration predicts cardiovascular outcomes: A systematic review and meta-analysis of prospective studies. European Heart Journal, 32(12), 1484–1492. https://doi.org/10.1093/eurheartj/ehr007

Cappuccio

F. P.

D’Elia

Strazzullo

Miller

M. A.

(2010). Sleep duration and all-cause mortality: A systematic review and meta-analysis of prospective studies. Sleep, 33(5), 585–592. https://doi.org/10.1093/sleep/33.5.585

Carpenter

Jolly

J. K.

Bridge

(2019). The elephant in the room: Understanding the pathogenesis of charles bonnet syndrome. Ophthalmic and Physiological Optics, 39(6), 414–421. https://doi.org/10.1111/opo.12645

10.

Chakravarthy

Wong

T. Y.

Fletcher

Piault

Evans

Zlateva

Buggage

Pleil

Mitchell

(2010). Clinical risk factors for age-related macular degeneration: A systematic review and meta-analysis. BMC Ophthalmology, 10, Article number 31. https://doi.org/10.1186/1471-2415-10-31

11.

Chattoraj

Liu

Zhang

L. S.

Huang

Borjigin

(2009). Melatonin formation in mammals: In vivo perspectives. Reviews in Endocrine and Metabolic Disorders, 10(4), 237–243. https://doi.org/10.1007/s11154-009-9125-5

12.

Chattu

V. K.

Manzar

M. D.

Kumary

Burman

Spence

D. W.

Pandi-Perumal

S. R.

(2018). The global problem of insufficient sleep and its serious public health implications. Healthcare (Basel), 7(1), Article 1. https://doi.org/10.3390/healthcare7010001

13.

Chew

Tan

N. Y. Q.

Lamoureux

Chenga

C.-Y.

Wonga

T. Y.

Sabanayagama

(2020). The associations of objectively measured sleep duration and sleep disturbances with diabetic retinopathy. Diabetes Research and Clinical Practice, 159, Article 107967. https://doi.org/10.1016/j.diabres.2019.107967

14.

Chin

J. Y.

Toh

Z. H.

Y. T.

Wang

H. T. Y.

Poh

E. Y. W.

Chua

C. H.

Hee

O. K.

Lim

B. A.

Yong

V. K. Y.

Laude

Wong

H. T.

Yip

L. W. L.

(2020). Effects of primary glaucoma on sleep quality and daytime sleepiness of patients residing at an equatorial latitude. International Journal of Ophthalmology, 13(9), 1451–1458. https://doi.org/10.18240/ijo.2020.09.18

15.

Cimarolli

V. R.

Casten

R. J.

Rovner

B. W.

Heyl

Sörensen

Horowitz

(2015). Anxiety and depression in patients with advanced macular degeneration: Current perspectives. Clinical Ophthalmology, 10, 55–63. https://doi.org/10.2147/OPTH.S80489

16.

Czeisler

C. A.

(1995). The effect of light on the human circadian pacemaker. Ciba Foundation Symposium, 183, 254–290. https://doi.org/10.1002/9780470514597

17.

Downs

S. H.

Black

(1998). The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of healthcare interventions. Journal of Epidemiology and Community Health, 52(6), 377–384. https://doi.org/10.1136/jech.52.6.377

18.

Enoch

Subramanian

Willig

(2024). How do research participants with age-related vision loss talk about their experiences? A secondary discourse analysis of published qualitative extracts. Ageing and Society, 45(6), 1104–1142. https://doi.org/10.1017/s0144686 ( 24000138

19.

Everson

C. A.

Laatsch

C. D.

Hogg

(2005). Antioxidant defense responses to sleep loss and sleep recovery. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 288(2), R374–R383. https://doi.org/10.1152/ajpregu.00565.2004

20.

Hackett

N. J.

Lauren

N. M.

Garg

P. G.

Gill

M. K.

Lyon

A. T.

Mirza

R. G.

(2018). Patients with dry age-related macular degeneration are at a higher risk for sleep apnea. Austin Journal of Clinical Ophthalmology, 5(3), Article 1098.

21.

Hanscom

T. A.

Kreiger

A. E.

(1980). Diurnal rhythms in macular degeneration. Annals of Ophthalmology, 12(9), 1058–1060.

22.

Hardeland

Pandi-Perumal

S. R.

Cardinali

D. P.

(2006). Melatonin. International Journal of Biochemistry & Cell Biology, 38(3), 313–316. https://doi.org/10.1016/j.biocel.2005.08.020

23.

Hassell

J. B.

Lamoureux

E. L.

Keeffe

J. E.

(2006). Impact of age-related macular degeneration on quality of life. British Journal of Ophthalmology, 90(5), 593–596. https://doi.org/10.1136/bjo.2005.086595

24.

Hillman

D. R.

Murphy

A. S.

Pezzullo

(2006). The economic cost of sleep disorders. Sleep, 29(3), 299–305. https://doi.org/10.1093/sleep/29.3.299

25.

Hyman

Schachat

Leske

M. C.

, for the Age-Related Macular Degeneration Risk Factors Study Group. (2000). Hypertension, cardiovascular disease, and age-related macular degeneration. Archives of Ophthalmology, 118(3), 351–358. https://doi.org/10.1001/archopht.118.3.351

26.

Iguchi

Kato

K. I.

Ibayashi

(1982). Age-dependent reduction in serum melatonin. Journal of Clinical Endocrinology & Metabolism, 55(1), 27–29. https://doi.org/10.1210/jcem-55-1-27

27.

Jong

P. E.

(2006). Age-related macular degeneration. New England Journal of Medicine, 355(14), 1474–1485. https://doi.org/10.1056/NEJMra062326

28.

Julio

Clifford

(1986). Age-associated changes in the circadian rhythm of retinal N-acetylserotonin and melatonin in rats with pigmented eyes. Experimental Gerontology, 21(1), 23–30. https://doi.org/10.1016/0531-5565(86)90014-8

29.

Jung

H. B.

Reiter

R. J.

Ahmad

(2010). Sirtuins, melatonin and circadian rhythms: Building a bridge between aging and cancer. Journal of Pineal Research, 48(1), 9–19. https://doi.org/10.1111/j.1600-079X.2009.00729.x

30.

Khurana

R. N.

Porco

T. C.

Claman

D. M.

Boldrey

E. E.

Palmer

J. D.

Wieland

M. R.

(2016). Increasing sleep duration is associated with geographic atrophy and age-related macular degeneration. Retina, 36(2), 255–258. https://doi.org/10.1097/IAE.0000000000000706

31.

Lane

Rohan

Sabeti

Essex

R. W.

Maddess

Dawel

Robbins

R. A.

Barnes

McKone

(2018). Impacts of impaired face perception on social interactions and quality of life in age-related macular degeneration: A qualitative study and new community resources. PLOS One, 13(12), Article e0209218. https://doi.org/10.1371/journal.pone.0209218

32.

Lee

Choh

A. C.

Demerath

E. W.

Knutson

K. L.

Duren

D. L.

Sherwood

R. J.

Sun

S. S.

Chumlea

W. C.

Towne

Siervogel

R. M.

Czerwinski

S. A.

(2009). Sleep disturbance in relation to health-related quality of life in adults: The fels longitudinal study. Journal of Nutrition, Health and Aging, 13(6), 576–583. https://doi.org/10.1007/s12603-009-0110-1

33.

Lockley

S. W.

Arendt

Skene

D. J.

(2007). Visual impairment and circadian rhythm disorders. Dialogues in Clinical Neuroscience, 9(3), 301–314. https://doi.org/10.31887/DCNS.2007.9.3/slockley

34.

Lockley

S. W.

Skene

D. J.

Arendt

Tabandeh

Bird

A. C.

Defrance

(1997). Relationship between melatonin rhythms and visual loss in the blind. Journal of Clinical Endocrinology & Metabolism, 82(11), 3763–3770. https://doi.org/10.1210/jcem.82.11.4355

35.

Martínez-Águila

Martín-Gil

Carpena-Torres

Pastrana

Carracedo

(2021). Influence of circadian rhythm in the eye: Significance of melatonin in glaucoma. Biomolecules, 11(3), Article 340. https://doi.org/10.3390/biom11030340

36.

Maynard

M. L.

Zele

A. J.

Kwan

A. S.

Feigl

(2017). Intrinsically photosensitive retinal ganglion cell function, sleep efficiency and depression in advanced age-related macular degeneration. Investigative Ophthalmology & Visual Science, 58(2), 990–996. https://doi.org/10.1167/iovs.16-20659

37.

Mistlberger

R. E.

Skene

D. J.

(2005). Nonphotic entrainment in humans? Journal of Biological Rhythms, 20(4), 339–352. https://doi.org/10.1177/0748730405277982

38.

Mitchell

Bradley

(2006). Quality of life in age-related macular degeneration: A review of the literature. Health and Quality of Life Outcomes, 4, Article number 97. https://doi.org/10.1186/1477-7525-4-97

39.

Morvaridzadeh

Sadeghi

Agah

Nachvak

S. M.

Fazelian

Moradi

Persad

Heshmati

(2020). Effect of melatonin supplementation on oxidative stress parameters: A systematic review and meta-analysis. Pharmacological Research, 161, Article number 105210. https://doi.org/10.1016/j.phrs.2020.105210

40.

Murphy

Duponsel

Huang

X. S.

Wittich

Koenekoop

R. K.

Overbury

(2015). Retinal disorders and sleep disorders: Are they genetically related? Journal of Visual Impairment & Blindness, 109(5), 359–370. https://doi.org/10.1177/0145482X1510900505

41.

Nau

J. A.

(2017). Association between age-related macular degeneration and sleep-disordered breathing [Doctoral dissertation, Walden University]. Walden Dissertations and Doctoral Studies. https://scholarworks.waldenu.edu/dissertations/3463

42.

Ohayon

M. M.

(2002). Epidemiology of insomnia: What we know and what we still need to learn. Sleep Medicine Reviews, 6(2), 97–111. https://doi.org/10.1053/smrv.2002.0186

43.

Pang

(2015). Visual hallucinations: Identifying charles bonnet syndrome. International Journal of Ophthalmology & Eye Science, 5(1), 14–22. https://doi.org/10.19070/2332-290x-si01004

44.

Parish

J. M.

(2009). Sleep-related problems in common medical conditions. Chest, 135(2), 563–572. https://doi.org/10.1378/chest.08-0934

45.

Pérez-Canales

J. L.

Rico-Sergado

Pérez-Santonja

J. J.

(2016). Self-reported sleep duration in patients with neovascular age-related macular degeneration. Ophthalmic Epidemiology, 23(1), 20–26. https://doi.org/10.3109/09286586.2015.1119288

46.

Purbrick

R. M. J.

Wong

J. C.

Safa

Alexander

Morjaria

Wulff

Foster

R. G.

Downes

S. M.

(2014). Sleep quality in age-related macular degeneration (AMD). Investigative Ophthalmology & Visual Science, 55(13), Article 3494.

47.

Revell

V. L.

Skene

D. J.

(2010). Impact of age on human non-visual responses to light. Sleep and Biological Rhythms, 8(2), 84–94. https://doi.org/10.1111/j.1479-8425.2009.00418.x

48.

Rosen

D. N.

Perez

Tai

G.-P.

Chen

Tone

McCormick

S. A.

Walsh

(2009). Urinary 6-sulfatoxymelatonin level in age-related macular degeneration patients. Molecular Vision, 15, 1673–1679.

49.

Roth

(2007). Insomnia: Definition, prevalence, etiology, and consequences. Journal of Clinical Sleep Medicine, 3(5 Suppl), S7–S10. https://doi.org/10.5664/jcsm.26929

50.

Roth

Roehrs

(2003). Insomnia: Epidemiology, characteristics, and consequences. Clinical Cornerstone, 5(3), 5–15. https://doi.org/10.1016/S1098-3597(03)90031-7

51.

Sack

R. L.

Lewy

A. J.

Blood

M. L.

Keith

L. D.

Nakagawa

(1992). Circadian rhythm abnormalities in totally blind people: Incidence and clinical significance. Journal of Clinical Endocrinology & Metabolism, 75(1), 127–134. https://doi.org/10.1210/jcem.75.1.1619000

52.

Saper

C. B.

Scammell

T. E.

(2005). Hypothalamic regulation of sleep and circadian rhythms. Nature, 437(7063), 1257–1263. https://doi.org/10.1038/nature04284

53.

Senra

Hernández-Moreno

Moreno

Macedo

A. F.

(2022). Anxiety levels moderate the association between visual acuity and health-related quality of life in chronic eye disease patients. Scientific Reports, 12(1), Article 2313. https://doi.org/10.1038/s41598-022-06252-1

54.

Senra

Macedo

A. F.

Nunes

Balaskas

Aslam

Costa

M. E.

(2019). Psychological and psychosocial interventions for depression and anxiety in patients with age-related macular degeneration: A systematic review. The American Journal of Geriatric Psychiatry, 27(8), 755–773. https://doi.org/10.1016/j.jagp.2019.03.001

55.

Sharma

Singh

Sharma

S. K.

, et al. (2021). Sleeping pattern and activities of daily living modulate protein expression in AMD. PLOS One, 16(6), Article e0249765. https://doi.org/10.1371/journal.pone.0249765

56.

Taylor

D. W.

Hobby

Binns

Crabb

D. P.

(2016). How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review. BMJ Open, 6(12), Article e011504. https://doi.org/10.1136/bmjopen-2016-011504

57.

Tsai

D. C.

Chen

H. C.

Leu

H. B.

Chen

S.-J.

Hsu

N.-W.

Huang

C.-C.

Chen

J.-W.

Lin

S.-J.

Chou

(2020). The association between clinically diagnosed insomnia and age-related macular degeneration: A population-based cohort study. Acta Ophthalmologica, 98(2), e238–e244. https://doi.org/10.1111/aos.14238

58.

Vallat

Shah

V. D.

Redline

Attia

Walker

M. P.

(2020). Broken sleep predicts hardened blood vessels. PLOS Biology, 18(6), Article e3000726. https://doi.org/10.1371/journal.pbio.3000726

59.

Wong

W. L.

Cheung

C. M. G.

Klein

Cheng

C.-Y.

Wong

T. Y.

(2014). Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. The Lancet Global Health, 2(2), e106–e116. https://doi.org/10.1016/S2214-109X(13)70145-1

60.

Worley

S. L.

(2018). The extraordinary importance of sleep: The detrimental effects of inadequate sleep on health and public safety drive an explosion of sleep research. Pharmacy and Therapeutics, 43(12), 758–763.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB

0.50 MB

0.02 MB